Previous Next


№3' 2014


International Medical Journal, Vol. 20., Iss. 3, 2014, P. 35−39.

Clinical features of ischemic stroke in patients with polymorphism of 5G/4G gene of type 1 plasminogen activator inhibitor

Sokolova L. I., Melnуk V. S., Savchuk A. N.

Bogomolets National Medical University, Ukraine
Institute of Biology, Taras Shevchenko National University, Kyiv, Ukraine

Clinical features of ischemic stroke in patients with polymorphism 5G/4G gene inhibitor of plasminogen activator 1. The aim of this study was to characterize neurological disorders in patients with ischemic stroke and polymorphism of 5G/4G PAI−1 gene, an important regulator of the fibrinolytic system. This clinical neurological and genetic study involved 113 patients (mean age 73.6±8.9 years) with acute ischemic stroke. Genotyping was performed using PCR−thermocycler "Eppendorf". Statistical analysis was performed using SPSS 17.0 and included one−way ANOVA and Pearson χ². When compared genotype frequencies of polymorphism 5G/4G PAI−1 gene in patients with ischemic stroke with the controls significant differences were not found. Fatal stroke in the first 14 days of the disease was reported in 17 (15 %) patients without significant differences between the groups (p = 0.12). The most favorable type of ischemic stroke course was reported in patients with genotype 5G/5G PAI−1 gene, they showed more complete recovery of neurological functions and on the 14th day of the stroke 34.8 % demonstrated complete resolution of neurological disorders and further 56.5 % showed mild neurological deficiency. Our findings demonstrate that polymorphism of 5G/4G PAI−1 gene is associated with clinical features of ischemic stroke. Patients with abnormal homozygous 4G/4G PAI−1 gene have more pronounced neurological deficiency during the first 14 days of the stroke, with a high mortality rate (21.3 %) and insufficient recovery of the neurological function by the end of the second week of ischemic stroke.

Key words: ischemic stroke, type 1 inhibitor of plasminogen activator, allelic polymorphism.

Go on Top